The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Gandhi, 2018, KEYNOTE 189 (adeno): pembrolizumab plus chemotherapy (carbo/pemetrexed) in metastatic non-small-cell lung cancer (adeno), N Engl J Med, 378, 2078, 10.1056/NEJMoa1801005

Paz-Ares, 2018, Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC), J Clin Oncol, 36, 105, 10.1200/JCO.2018.36.15_suppl.105

Peters, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) versus platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis, Ann Oncol, 30, v851, 10.1093/annonc/mdz394.075

Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N Engl J Med, 378, 2288, 10.1056/NEJMoa1716948

Pacheco, 2019, A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer, Front Oncol, 9, 195, 10.3389/fonc.2019.00195

Listì, 2019, Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer, Transl Cancer Res, 8, S55, 10.21037/tcr.2018.10.04

Rossi, 2020, Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient, Cancers (Basel), 12, 1125, 10.3390/cancers12051125

Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7

Hellmann, 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer, N Engl J Med, 381, 2020, 10.1056/NEJMoa1910231

Ready, 2019, First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers, J Clin Oncol, 37, 992, 10.1200/JCO.18.01042

Chan, 2019, Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann Oncol, 30, 44, 10.1093/annonc/mdy495

Carbone, 2017, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, 376, 2415, 10.1056/NEJMoa1613493

Friedlaender, 2020, Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors, Front Oncol, 10, 142, 10.3389/fonc.2020.00142

Lu, 2019, Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis, JAMA Oncol, 5, 1195, 10.1001/jamaoncol.2019.1549

Galuppini, 2019, Tumor mutation burden: from comprehensive mutational screening to the clinic, Cancer Cell Int, 19, 209, 10.1186/s12935-019-0929-4

Kim, 2019, Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis, Cancers (Basel), 11, 1798, 10.3390/cancers11111798

Pawelczyk, 2019, Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers, Int J Mol Sci, 20, 824, 10.3390/ijms20040824

Incorvaia, 2019, Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC), Adv Ther, 36, 2600, 10.1007/s12325-019-01057-7

Yarchoan, 2019, PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers, JCI Insight, 4, e126908, 10.1172/jci.insight.126908

Chen, 2019, PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer, J Exp Clin Cancer Res, 38, 193, 10.1186/s13046-019-1192-1

Nacchio, 2020, KRAS mutations testing in non-small cell lung cancer: the role of liquid biopsy in the basal setting, J Thorac Dis, 12, 3836, 10.21037/jtd.2020.01.19

Willis, 2019, Tumor mutational burden in lung cancer: a systematic literature review, Oncotarget, 10, 6604, 10.18632/oncotarget.27287

Greillier, 2018, The clinical utility of tumor mutational burden in non-small cell lung cancer, Transl Lung Cancer Res, 7, 639, 10.21037/tlcr.2018.10.08

Hendriks, 2018, Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy, Transl Lung Cancer Res, 7, 647, 10.21037/tlcr.2018.09.22

Berland, 2019, Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors, J Thorac Dis, 11, S71, 10.21037/jtd.2018.11.102

Reck, 2018, Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer, Immunotherapy, 10, 93, 10.2217/imt-2017-0121

Herbst, 2019, Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials, Ann Oncol, 30, V916, 10.1093/annonc/mdz394.077

Paz-Ares, 2019, Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407, Ann Oncol, 30, v851, 10.1093/annonc/mdz394.078

Socinski, 2019, Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC), Ann Oncol, 30, v919, 10.1093/annonc/mdz394.081

Hellmann, 2018, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden, N Engl J Med, 378, 2093, 10.1056/NEJMoa1801946

Rizvi, 2020, Durvalumab with or without tremelimumab versus standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial, JAMA Oncol, 6, 661, 10.1001/jamaoncol.2020.0237

Spigel, 2019, IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC, Ann Oncol, 30, v851

2014

Borenstein, 2005

Borenstein, 2010, A basic introduction to fixed-effect and random-effects models for meta-analysis, Res Synth Methods, 1, 97, 10.1002/jrsm.12

Higgins, 2019

Wu, 2019, The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis, Front Oncol, 9, 1161, 10.3389/fonc.2019.01161

Alborelli, 2020, Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer, J Pathol, 250, 19, 10.1002/path.5344

Heeke, 2018, Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?, Transl Lung Cancer Res, 7, 631, 10.21037/tlcr.2018.08.04

Addeo, 2019, JCSE01.05 Biomarker in immunotherapy: myth or reality?, J Thorac Oncol, 14, S126, 10.1016/j.jtho.2019.08.265

Goodman, 2020, MHC-I genotype and tumor mutational burden predict response to immunotherapy, Genome Med, 12, 45, 10.1186/s13073-020-00743-4

Shim, 2020, HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients, Ann Oncol, 31, 902, 10.1016/j.annonc.2020.04.004

Chen, 2019, Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis, Thorac Cancer, 10, 607, 10.1111/1759-7714.12971

Lim, 2020, Immunotherapy for non-small cell lung cancer: current landscape and future perspectives, Immune Network, 20, e10, 10.4110/in.2020.20.e10

Rizvi, 2018, Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, 36, 633, 10.1200/JCO.2017.75.3384

Sholl, 2020, Tumor mutation burden: promises and challenges a perspective from the IASLC pathology committee, J Thorac Oncol, 15, 1409, 10.1016/j.jtho.2020.05.019

Stenzinger, 2019, Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions, Genes Chromosom Cancer, 58, 578, 10.1002/gcc.22733

Vokes, 2019, Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer, JCO Precis Oncol, 3

Kim, 2019, Efficacy of cancer immunotherapy: an umbrella systematic review and meta-analyses of randomized controlled trials from - articles and - original meta-analyses, PROSPERO, 11, 1801

Chae, 2018, Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC), J ImmunoTherapy of Cancer, 6, 39, 10.1186/s40425-018-0349-3

Tsiara, 2018, Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), Ann Transl Med, 6, 144, 10.21037/atm.2018.02.07

Ettinger, 2019, Non-small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines, J Natl Compr Cancer Netw, 17, 1464, 10.6004/jnccn.2019.0059

Addeo, 2019, Tumor mutation burden-from hopes to doubts, JAMA Oncol, 5, 934, 10.1001/jamaoncol.2019.0626